A Phase 1 interventional study of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine and 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine in Pneumococcal Infections, sponsored by Wuhan BravoVax Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 6 Weeks and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-17.
Sponsored by Wuhan BravoVax Co., Ltd. · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 26th largest by planned enrollment, is one of 3 that started in 2022, is one of 6 in phase 1, and was the 42nd registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 6 Weeks and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 264 is below the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Wuhan BravoVax Co., Ltd. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Wuhan BravoVax Co., Ltd. has 1 study filed under Pneumococcal Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year. Since the licensure of PCV7, PCV10, PCV13 and PCV15, the reported overall decline in invasive pneumococcal disease in hospitalized children younger than 5 years is approximately 60% around the world.
This is a single center, blinded, randomized, positive-controlled phase I clinical trial to evaluate the safety and explore the immunogenicity of a candidate PCV13 in healthy people aged 2 months (minimum 6 weeks) and above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received one dose of PCV13 at 18 years of age and above.
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received one dose of PCV13 at 6\~17 years of age.
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received one dose of PCV13 at 2\~5 years of age.
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received two doses of PCV13 at 12\~23 months of age.
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received three doses of PCV13 at 7\~11 months of age.
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received four doses of PCV13 at 3 months of age.
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old).
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received four doses of control PCV13 at 2 months of age (At least 6 weeks old).
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old).
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received four doses of control PCV13 at 2 months of age (At least 6 weeks old).
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
0.5mL, Intramuscular
Also known as: PCV13
0.5mL, Intramuscular
Also known as: Prevnar 13
Safety in terms of adverse reactions
Occurrence of AEs on vaccination site (local) and non-vaccination site (systemic) of each subject
Time frame: within 30 minutes post each vaccination
Safety in terms of adverse events
Occurrence of solicited AEs of each subject
Time frame: within 7 days post each vaccination
Safety in terms of adverse events
Occurrence of non-solicited AEs of each subject
Time frame: within 30 days post each vaccination
Safety in terms of SAEs
Occurrence of SAEs of each subject
Time frame: within 6 months post last vaccination
Safety in terms of laboratory-based AEs
Occurrence of laboratory-based AEs in subjects of 2 years old and above(Arm 1A-3A)
Time frame: within 4 days post each vaccination
Immunogencity in terms of seropositivity rates by ELISA
Seropositivity rates of serotype-specific pneumococcal IgG antibody in subjects of each age group
Time frame: 30 days post basic vaccination
Immunogencity in terms of GMC by ELISA
GMC of serotype-specific pneumococcal IgG antibody in subjects of each age group
Time frame: 30 days post basic vaccination
Immunogencity in terms of subjects with IgG concentrations ≥1.0 µg/mL
Percentage of subjects with serotype-specific IgG concentrations ≥1.0 µg/mL
Time frame: 30 days post basic vaccination
Immunogencity Comparison with control vaccine group
Comparison of the seropositivity rates, GMC of serotype-specific pneumococcal IgG antibody and the Percentage of subjects with serotype-specific IgG concentrations ≥1.0 µg/mL in subjects aged 2 months of Experimental group and Control group
Time frame: 30 days post basic vaccination
Started Nov 2022 (actual). Primary completion is estimated for Jun 2024, 19 months after the start.
Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 19 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wuhan BravoVax Co., Ltd.